Researchers are beginning work on a double-blind randomized controlled trial to test the results of this preliminary study. A 1-hour endoscopic procedure could potentially eliminate the need for ...

PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the ...

Type 2 diabetes is one of the most common health problems in the world today. In the United States alone, more than 37 ...

*A gene therapy that may eliminate, or significantly reduce, the need for daily insulin injections is preparing to enter human trials for the first time, offering fresh hope to hundreds of thousands ...

Researchers compared the efficacy of once-weekly and once-daily insulin treatments for type 2 diabetes. They found that the once-weekly treatment icodec was more effective in lowering blood sugar ...

Data were obtained through an Internet survey of U.S. adults self-identified as taking insulin to treat type 1 or type 2 diabetes; the survey was conducted 13 June to 7 July 2008 by Harris Interactive ...

SUPER-1 is a 52-week (26-week main phase plus 26-week extension phase), phase 3, treat-to-target trial investigating the efficacy and safety of once-weekly GZR4 versus once-daily insulin glargine U100 ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...